Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors

Trial Profile

Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2018

At a glance

  • Drugs Cabiralizumab (Primary) ; Nivolumab (Primary) ; Urelumab (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms C4-MOSART
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 09 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 16 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top